NCT01337804

A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)

A Single Dose, Comparative, Open-label, Randomized, Crossover Bioequivalence Study of Omeprazole Administered as Zegerid® Powder for Oral Suspension 20 mg and Prilosec 40 mg Capsule in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study compares the bioequivalence of omeprazole administered as either Zegerid® powder for oral suspension 20 mg or as Prilosec 40 mg capsule to healthy participants.

Conditions

• Heartburn

Interventions

Type	Name	Description
DRUG	omeprazole/sodium bicarbonate	Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
DRUG	omeprazole magnesium	Single 40 mg capsule of omeprazole given orally

Timeline

• Start date: 2011-01-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2011-04-19
• Last updated: 2015-02-23